Company intelligence / Profile preview

Dash Bio

United States

Ownership: Private
Development stage: Other

Overview

Dash Bio operates an automated, GLP-compliant laboratory providing high-quality and dramatically accelerated clinical bioanalysis. Their technology-first approach leverages AI and robotics to deliver assay results up to 10 times faster than industry averages for clinical trials and GLP studies. The company’s focus on automation enables rapid turnaround for core assays supporting in vivo through late-stage clinical studies.

Modalities: small moleculesbiologicsmRNA
Industry: Contract Research Organization

Beyond the preview

Go deeper on Dash Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dash Bio.

Explore the full profile